drug · small molecule
patient view →DEFLAZACORT
Marketedupdated 2mo agoby $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for muscular dystrophy and duchenne muscular dystrophy and 3 investigational indications.
indications
investigational
Duchenne Muscular Dystrophy
targets
Glucocorticoid receptor
all catalysts(3)
approval · 3
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that